But it showed a consistent trend that DLBCL patients with co-expression of p-AKT and PD-L1 had worse prognosis compared to patients with single positive or both negative expression of PD-L1 and p-AKT, who were treated with either R-CHOP or CHOP/CHOPE. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.